Fungal Nail Infection (Onychomycosis): Exposure Risks, Diagnosis & Treatment

Onychomycosis is an infection of the nail plate, nail bed and—when long-standing—the nail matrix, caused predominantly by dermatophytes (especially Trichophyton rubrum and T. mentagrophytes) and, less commonly, by non-dermatophyte moulds (Scopulariopsis, Aspergillus, Fusarium) and Candida species. Toenails carry the bulk of disease because slower growth, micro-trauma from footwear and a humid microenvironment all favour fungal persistence.

The infection typically begins at the distal or lateral edge of the nail, advances proximally through the nail bed, and produces yellow-brown discoloration, subungual hyperkeratotic debris, separation of the nail plate from the bed (onycholysis) and progressive thickening, brittleness or crumbling. It is rarely painful at first and is therefore often dismissed as cosmetic; the clinical importance is the reservoir effect (continually re-seeding adjacent skin and the contralateral foot), the impact on mobility and footwear in older adults, and the role of the disrupted nail unit as an entry point for bacterial cellulitis—particularly in patients with diabetes, vascular disease or immunosuppression.

Onychomycosis is grouped clinically by the route of fungal invasion. Recognising the subtype matters because it shapes the chance of cure with topical-only therapy, the urgency of mycology, and—in some cases—the search for an underlying immune problem.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice note: for documentation, simple descriptors (number of nails involved, percent of plate affected, matrix involvement, presence of dermatophytoma or longitudinal streaks) are more useful at handover than memorising every named subtype.

Most patients present after months to years of slow nail change, often noticed first when shoes get tight, when polish lifts, or during a routine foot check. Pain is uncommon early but emerges as nails thicken and press against footwear or as paronychia develops.

Typical features

• Yellow-brown, white or grey discoloration of one or more toenails, frequently starting at the distal edge.
• Subungual hyperkeratosis with crumbly debris under the nail plate.
• Onycholysis (separation of nail plate from bed), often visualised as a creamy-yellow proximal advancing edge.
• Thickening, brittleness or splitting of the nail plate; loss of normal lustre.
• Concurrent tinea pedis in interdigital spaces or as moccasin-pattern plantar scaling.

Atypical or under-recognised presentations

• Superficial white islands on the dorsal plate that can be gently scraped off—often missed and treated as a cosmetic problem.
• Proximal subungual change beginning under the cuticle in an otherwise well adult—a flag for immune compromise.
• Fingernail-only disease with surrounding nail-fold inflammation in someone with wet-work exposure—suspect Candida and chronic paronychia rather than dermatophyte.
• Painful or rapidly thickening single nail—reconsider trauma, psoriasis or melanoma before assuming fungus.
• Recurrent itching and scaling between toes that flares each summer—often the dermatophyte reservoir for the nail disease.

Why does it happen?

Dermatophytes secrete keratinases that digest nail keratin and migrate proximally through the nail bed; once the matrix is involved, the entire growing nail plate may be affected. Non-dermatophyte moulds and Candida exploit damaged or wet nails, often after repeated nail-fold trauma or chronic immersion.

Host (non-modifiable) risk factors

• Increasing age—prevalence rises sharply after 60, partly reflecting cumulative exposure, slower nail growth and reduced peripheral perfusion.
• Male sex (toenail dermatophyte disease).
• Family clustering with apparent autosomal-dominant susceptibility to T. rubrum.
• Peripheral arterial disease, chronic venous insufficiency, lymphoedema.
• Type 2 diabetes and type 1 diabetes—roughly two- to three-fold higher onychomycosis prevalence and worse complication risk.
• Immunocompromise (HIV/AIDS, transplant immunosuppression, haematological malignancy, prolonged systemic corticosteroids, biologic therapy).

External / modifiable amplifiers

• Untreated tinea pedis or tinea cruris acting as a fungal reservoir.
• Occlusive non-breathable footwear; shared shower spaces; communal swimming pools and locker rooms.
• Repeated nail trauma in runners, dancers, military personnel and patients with toe-box deformity.
• Aggressive cosmetic manicures, acrylic nails and shared nail tools at salons.
• Hyperhidrosis and prolonged use of damp socks or boots.

Clinical assessment

Nurses contribute a structured skin assessment covering all 20 nails plus interdigital spaces, soles, palms and groin (synchronous tinea is common); a foot pulse and monofilament check when diabetes or vascular disease is on the chart; an admission medication review for hepatotoxic and CYP-interacting drugs; and consented photography for serial comparison. Document number of nails involved, percentage of plate affected, matrix involvement, presence of paronychia and any pigmented streaks.

Mycology — confirmation before months of therapy

Major dermatology guidelines (AAD, NICE/CKS, BAD) recommend laboratory confirmation before starting oral antifungals because clinical diagnosis alone is wrong in around half of cases. Take an adequate sample with clean clippers from the most proximal abnormal nail tissue, plus subungual debris, after disinfecting the surface to avoid contaminant overgrowth.

• Direct microscopy with KOH (± chlorazol black or calcofluor white) — fast, modest sensitivity, cannot speciate.
• Fungal culture — speciation aids choice of therapy and identifies non-dermatophyte moulds; slow (2–6 weeks) and falsely negative in ~30%.
• PAS-stained nail clipping (histopathology) — high sensitivity, particularly when culture is negative but clinical suspicion remains.
• Real-time fungal PCR — high sensitivity and specificity, rapid speciation, increasingly available in tertiary services.
• Targeted bacterial swab if purulence, marked nail-fold inflammation or suspected secondary infection.

Pre-treatment workup before oral antifungals

Coordinate with the prescriber on:

• Baseline liver function tests for terbinafine and itraconazole; consider repeat at 4–6 weeks per local pathway.
• Baseline complete blood count and renal screen for prolonged or repeated courses, especially with comorbidity.
• Comprehensive interaction screen (warfarin, statins, antiarrhythmics, calcineurin inhibitors, certain antidepressants, midazolam, etc.).
• Pregnancy avoidance counselling—itraconazole is contraindicated in pregnancy and terbinafine is generally deferred.
• Cardiac screen for itraconazole (history of congestive heart failure is a contraindication per the FDA boxed warning).

Imaging and biopsy

Imaging is not part of routine onychomycosis diagnosis. Plain radiographs are reserved for suspected osteomyelitis under a chronic ulcerated nail. Nail-matrix biopsy is the gateway investigation for suspected subungual melanoma and should not be delayed by an empirical antifungal trial.

About half of dystrophic nails referred as onychomycosis turn out to be something else; the cost of a mislabel is months of unnecessary oral therapy or, worse, a missed melanoma. Compare distribution, tempo and skin findings and re-test rather than re-prescribe.

↔On a small screen, swipe or scroll sideways to see the full table.

Therapy is layered: confirm the diagnosis, decide whether to treat (cosmetic-only disease in a low-risk patient is a legitimate “monitor” option), choose oral or topical based on extent and host factors, address the foot reservoir, and plan a 9–12 month follow-up window because clinical clearance lags well behind mycological cure.

First-line oral therapy (dermatophyte disease)

• Oral terbinafine 250 mg once daily for 12 weeks for toenails (6 weeks for fingernails). Highest mycological cure rates in dermatophyte disease in head-to-head trials and Cochrane review.
• Baseline LFTs; recheck per local policy; counsel on rare hepatotoxicity, taste disturbance and rash.
• Reassess at end of course rather than at 12 weeks—the new nail must grow out before clinical clearance is visible.

Oral alternatives

• Itraconazole pulse therapy 200 mg twice daily for one week per month, three pulses for fingernails and three to four for toenails (continuous 200 mg daily for 12 weeks is an alternative). Useful for non-dermatophyte moulds, Candida, terbinafine intolerance and broader-spectrum needs. Heavy CYP3A4 interaction profile; contraindicated in heart failure and pregnancy.
• Fluconazole 150–450 mg once weekly until clinical clearance—reasonable when terbinafine and itraconazole are contraindicated, though cure rates are lower.
• Griseofulvin retains a niche in paediatric dermatophyte infection where other oral agents are unsuitable; long courses, lower cure rates.

Topical therapy

• Efinaconazole 10% solution daily for 48 weeks—approved for dermatophyte toenail onychomycosis; better penetration than older lacquers.
• Tavaborole 5% solution daily for 48 weeks—comparable indications.
• Ciclopirox 8% nail lacquer daily with weekly removal for 48 weeks—lower complete-cure rates but well established.
• Amorolfine 5% lacquer once or twice weekly (where licensed).
• Topical clotrimazole or ketoconazole creams help control concurrent skin tinea but do not penetrate the nail plate adequately on their own.

Mechanical and surgical adjuncts

• Regular podiatry-led debridement reduces fungal load, improves topical penetration and helps comfort and footwear fit.
• Selective chemical (urea-based) or surgical avulsion of severely dystrophic nails in combination with oral or topical therapy can salvage otherwise treatment-resistant disease.
• Device-based therapies (lasers, photodynamic therapy) have weaker evidence and are generally reserved for patients who cannot tolerate or have failed other approaches.

Special populations

• Diabetes: treat actively because of cellulitis risk; coordinate with podiatry; preserve oral antifungal candidacy by checking interactions with sulfonylureas, statins and DPP-4 inhibitors.
• Hepatic impairment / cirrhosis: avoid oral antifungals where possible; favour topical lacquers and debridement; if oral therapy is unavoidable, specialist-led with closer LFT monitoring.
• Chronic kidney disease: dose adjustments may be needed for fluconazole; terbinafine generally avoided when creatinine clearance <50 mL/min unless specialist input.
• Pregnancy / lactation: defer oral antifungals; itraconazole contraindicated in pregnancy; modest topical therapy or simple debridement until after delivery.
• Children: oral terbinafine is widely used in paediatric tinea capitis and unguium, weight-based; involve paediatric dermatology for confirmation and dosing.
• Older adults: review polypharmacy carefully; consider whether the cosmetic and infection-control gains justify systemic therapy in a fragile host.

Workflow anchors: confirm with mycology → screen for hepatic, cardiac and interaction risks → choose oral or topical based on extent and host factors → treat the foot reservoir at the same time → schedule structured follow-up tied to drug, not symptom.

• Monitoring intervals: review at 4–6 weeks for tolerability and LFTs (oral therapy), at 3 months to confirm course completion, and at 9–12 months for clinical clearance assessment with repeat mycology if appearance is incomplete.
• Treatment failure criteria: persistent positive mycology at end of course; clinical worsening despite adherence; new nails involved; or recurrence within 12 months. Trigger reassessment of subtype, organism, adherence and reservoir control before re-treating.
• Stop rules: any unexplained transaminase rise >3× upper limit, new jaundice, dark urine, anorexia or right-upper-quadrant pain on oral antifungals—pause and review the same day.
• Referral thresholds: diagnostic doubt despite negative mycology; suspected nail-unit melanoma; severe nail psoriasis pattern; immunocompromise with proximal subungual disease; recurrent treatment failure; surgical avulsion candidacy; complicated diabetic foot.
• Infection-control teaching: reinforce hand hygiene after foot or nail contact, dedicated towels, footwear in communal showers, antifungal powder in shoes and avoidance of shared nail tools to limit autoinoculation and household spread.

Clinical decision flow (shift-ready)

1. Suspected fungal nail → take adequate clippings and subungual debris for KOH ± culture or PCR before any antifungal is prescribed.
2. Mycology positive, <50% nail involved, no matrix involvement, single or two nails → discuss topical lacquer (efinaconazole, tavaborole or ciclopirox).
3. Mycology positive with matrix involvement, >50% nail, multiple nails or treatment-failed topicals → arrange oral therapy with baseline LFTs and interaction review.
4. Comorbidity (diabetes, vascular disease, immunocompromise) → involve podiatry early, treat concurrent tinea pedis, lower threshold for prompt review of any new erythema or ulceration.
5. Single thumb / great toe with pigmented streak or rapid change → dermatology review for biopsy before starting antifungal therapy.

Bedside monitoring checklist

• Pain score, capillary refill, pedal pulses and skin warmth at baseline; flag any change.
• Photograph affected nails with a ruler at baseline and at each review.
• Review LFT trend if on oral therapy and any new gastrointestinal symptoms.
• Monofilament and visual foot exam in patients with diabetes; document any breach in skin integrity.
• Reconcile new prescriptions with the antifungal interaction list at every encounter.

• Bacterial superinfection of the nail unit and surrounding tissue, including cellulitis, lymphangitis or abscess—particularly in diabetes and peripheral vascular disease.
• Permanent nail dystrophy and scarring from long-standing matrix involvement.
• Pain, gait disturbance and reduced mobility in older adults due to thickened nails pressing on footwear.
• Recurrent tinea pedis driven by the nail reservoir, with subsequent dermatophyte spread to groin (tinea cruris) or trunk (tinea corporis).
• Drug-related adverse events from prolonged oral antifungals: hepatotoxicity, taste disturbance and rash with terbinafine; gastrointestinal upset, hepatic injury and rare congestive heart failure with itraconazole; QT-prolongation interactions with fluconazole.
• Psychosocial impact—embarrassment, avoidance of open footwear, occupational concerns for client-facing roles.

Clinically meaningful prevention combines control of the foot dermatophyte reservoir, environmental hygiene and footwear choice. Patients who treat their nails but ignore the surrounding skin tend to relapse.

• Treat any active interdigital or moccasin athlete’s foot alongside (or before) starting nail therapy.
• Encourage breathable footwear, alternate-day shoe rotation, moisture-wicking socks and prompt change after sweating.
• Use antifungal foot powder in shoes during high-risk seasons; consider replacing or disinfecting heavily contaminated footwear at the end of treatment.
• Wear shower footwear in communal wet areas (gyms, pools, dorms, hospital wards).
• Avoid sharing nail clippers, files or pumice stones; sterilise tools between use, especially in salon settings.
• Address modifiable host factors when feasible: glycaemic control, oedema management, smoking cessation, treatment of contributing dermatoses.

Reported mycological cure with oral terbinafine for dermatophyte toenail disease is in the order of 70–80% in adherent adults, with complete clinical and mycological cure (a fully normal nail) closer to 35–50% because the new nail takes 9–12 months to grow out and residual cosmetic dystrophy is common. Itraconazole pulse therapy gives slightly lower mycological cure but a comparable real-world outcome. Topical lacquers achieve complete cure in roughly 15–35% of mild distal disease, with adherence over 48 weeks the dominant determinant. Recurrence rates of 20–25% within three years are well described, almost always linked to under-treated foot tinea, environmental exposure or unmodifiable host factors. Realistic counselling—”clearer, not necessarily perfect”—prevents adherence collapse and unnecessary repeat courses.

Communication and equity

Discoloration looks different on richly pigmented nail beds—rely on subungual debris, plate distortion and onycholysis as much as colour. Older adults may not volunteer foot complaints; build a brief nail check into every diabetic foot review, vascular assessment and pre-operative skin survey. For wheelchair users and patients with limited reach or vision, explicit teaching on safe self-debridement (or referral to podiatry) is part of the prescription, not an afterthought.

Medication safety

Oral antifungals are some of the most interaction-prone outpatient drugs. Coordinate with pharmacy on warfarin, statins, calcineurin inhibitors, midazolam, certain antiarrhythmics and many psychiatric medications before the first dose. Reinforce the symptoms that should trigger same-day review—jaundice, dark urine, fatigue with anorexia, right-upper-quadrant pain or new rash—rather than relying on scheduled blood tests alone.

Documentation prompts

Note number of nails involved, percentage of plate, matrix involvement, confirmed mycology result, baseline LFT, footwear and occupational exposures, household cases, glycaemic control if relevant, and a clear date for end-of-course review. Anchor follow-up in months from drug start, not symptoms—patients who feel “no different at week 8” often stop early.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of fungal-nail-infection (onychomycosis) recognition (KOH / fungal culture / PCR), structured topical / oral terbinafine / itraconazole ladder and the diabetic-foot / immunocompromised / drug-toxicity red flags.